trial

Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?

NCTId NCT00206986
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 40 (estimated)
Sponsored by Birte Glenthoj
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2005-05
Primary completion
2011-12
Eligibility
MALE · 18 Years · 45 Years

Interventions & indications

Drugs
Clonidine

Sponsors

Birte GlenthojLead Sponsor
University of CopenhagenCollaborator
Lundbeck Canada Inc.Collaborator
Glostrup University Hospital, CopenhagenCollaborator

Investigators

1
Birte Glenthoj, MD, DMSc.Study Director

Sites

1 total
Copenhagen NV, Denmark

Facts & assertions

4 sourced
Enrollment
40
Phase
NA
Primary Completion Date
2011-12
Status
COMPLETED
relationships
The graph out of here
drug
Clonidine
drug
lead_sponsor
Birte Glenthoj
company
collaborator
University of Copenhagen
company
Lundbeck Canada Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Birte Glenthoj, MD, DMSc.
person